Despite the remarkable ability of nanomedicines to diagnose and treat disease, activation of the immune system and the development of innate and adaptive immunity against specific subsets of nanomedicines is a significant unresolved challenge.
Targeted alpha-therapies (TATs) are emerging as powerful radiopharmaceutical tools for cancer treatment, allowing precise and localised dosing of highly potent radiotherapy.
Nanomedicine, the application of nanotechnology and biotechnology to medicine, is a rapidly expanding field of research with great promise for making meaningful changes in the way we treat many diseases including cancer.
In radiotherapeutics, a wide range of organic ligands have been designed to coordinate inorganic radioisotopes for diagnostic or therapeutic purposes. These ligands are typically conjugated to a targeting moiety through a linker; an organic bridge between the ligand and the targeting moiety.
Researchers from the Australian Institute for Bioengineering and Nanotechnology (AIBN) have won $1.5 million to improve precision nanomedicines and create a cleaner environment – all while strengthening industry ties.
As we close the book on 2022 it is time to look at how far the AIBN has come during the year, and how we are setting ourselves up for an even bigger 2023.
An Australian-first research and manufacturing hub at the University of Queensland will lead the design and development of the next-generation of treatments for cancer patients.
AIBN's Professor Kristofer Thurecht and IMB's Professor Robert Parton and are Eureka Prize finalists for their project using VR to solve the problem of visualising complex data.
